Cadila Healthcare Limited and its subsidiary Zydus Pharmaceuticals has announced that they have reached an agreement with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb relating to patents for REVLIMID.
As part of the settlement, the Parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Zydus Cadila from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement.
On Wednesday trading session at 2:00 PM, Cadila Healthcare was trading at Rs435 per piece up by Rs3.95 or 0.92% from its previous closing of Rs431.05 per piece on Sensex.